Pfizer Stock

Pfizer EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Pfizer (PFE) as of Aug 5, 2026 is 15.78. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was 20.41 — a change of -22.67% (lower).

EV/FCF

15.78

YoY

-22.67%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Pfizer is 2026 15.78 . EV/FCF (Enterprise Value to Free Cash Flow) of Pfizer was 2025 20.41 . It decreases by -22.67% lower compared to the previous year.
Access this data via the Eulerpool API

Pfizer Stock analysis

What does Pfizer do? Pfizer Inc, one of the world's largest and most well-known pharmaceutical companies, has made significant advancements in the medical industry throughout its approximately 170-year history. The company is headquartered in New York City and has offices in over 150 countries. Pfizer was founded in 1849 by two cousins, Charles Pfizer and Charles Erhart, who opened their first factory in Brooklyn to produce pure crystalline chinasalt. They later expanded their business and began synthesizing chemical compounds, leading them to enter the pharmaceutical industry. In the following years, Pfizer made some significant discoveries, including the synthesis of antibiotics such as penicillin and terramycin. In the 1990s, the company expanded its portfolio and became a leading provider of prescription drugs, immunological medications, and animal health products. Today, the company focuses on three core areas: innovative health products, patented medications, and generic products. Pfizer invests millions of dollars in research and development of new and innovative treatment options, including cancer drugs, therapies for neurological disorders, cardiovascular diseases, and immunology products. Another important aspect of Pfizer's business model is its partnerships with other companies and organizations. The company works closely with universities, research institutions, governments, and other companies to form partnerships that allow for collaborative development of new products. Some of Pfizer's most well-known products include Viagra, Lipitor, Celebrex, Zoloft, and Lyrica. Viagra is used to treat erectile dysfunction in men. Lipitor is a cholesterol-lowering medication that reduces the risk of cardiovascular diseases. Celebrex is an anti-inflammatory medication used to treat pain and inflammation. Zoloft is an antidepressant used to treat various mental disorders. Lyrica is a prescription medication used to treat pain and seizures. In recent years, Pfizer has also taken a leading role in the development of vaccines against COVID-19, collaborating with the German company BioNTech to develop a promising vaccine candidate. The vaccine provides protection against the virus, particularly against severe illness. Over the years, the company has faced concerns regarding the use of medications, such as the scandal surrounding the pain reliever Vioxx, which was withdrawn in 2004 after being associated with an increased risk of cardiovascular diseases. Pfizer has since strengthened its research and development standards and partnerships to ensure the safety and efficacy of its products. In summary, Pfizer is a global player in the pharmaceutical industry. The company heavily invests in research and development of new products to provide innovative treatment options, secures patents, and simultaneously keeps its portfolio up-to-date with generic products to remain competitive in the industry. The company will continue to contribute to improving healthcare worldwide by developing lifesaving medications and vaccines that enable people to lead better lives. Pfizer is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Pfizer stock

EV/FCF (Enterprise Value to Free Cash Flow) of Pfizer is 15.78 in 2026.

EV/FCF (Enterprise Value to Free Cash Flow) of Pfizer changed from 20.41 to 15.78, representing a -22.67% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Pfizer since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Pfizer with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Pfizer

All Key Metrics — Pfizer